Audit: QRS - Black Chokeberry for Health & Longevity

Audit conducted on 17/08/2026 06:19 using AI4L / Opus 5

Iterations

Summary

Items	Count
Total	93
Passed	84
Failed	0
N/A	9
Pass Rate	100.00%

• Total = Passed + Failed + N/A
• Pass Rate = Passed / (Passed + Failed) × 100
• N/A items are excluded from the pass rate calculation

---

1. General Rules

#	Description	Result	Comments
1.1	Every claim, magnitude, label, recommendation, and statement in the QRS is literally supported by content in the source ER.	🟢	Spot-checked protocol values (300–500 mg, >50 mg anthocyanins, 85–100 mg 2–3×/day), time-to-effect figures, all 7 contraindications, all 12 interactions, all 11 markers and the cadence sentence against ER lines 316–348, 372–394, 435, 465–479.
1.2	Where the ER uses cautious phrasing (“not formally studied”, “None documented in human trials to date”, “theoretical concern”, “data are limited”), the QRS uses the same phrasing.	🟢	No ER hedge is converted into a definite statement; at-a-glance retains “thin, inconsistent, and largely industry-funded” from ER lines 513–515.
1.3	The QRS never strengthens an ER claim (e.g., “not formally studied” → “not required”) or softens one (e.g., “do not use during pregnancy” → “use with caution during pregnancy”).	🟢	Avoid-population items remain absolute gates; interaction items remain interactions.
1.4	The QRS does not relabel an ER fact under a different decision category. A “Benefit-Modifying Factor” from ER section is not surfaced as a “Caution”; a “Risk-Modifying Factor” is not surfaced as a “Side Effect”; etc.	🟢	Contraindications come from the ER “Populations who should avoid” list, Key Interactions from the ER interaction bullets, Benefits/Risks from their own tiers; no Benefit- or Risk-Modifying Factor is surfaced.
1.5	PubMed IDs, study citations, expert names, clinical trial identifiers (NCT*), and brand names appear in the QRS only if they appear in the source ER for the same fact.	🟢	No PMID, NCT ID, author name or brand appears anywhere in the QRS; the ER’s “Examine” attribution in the dose bullet was correctly dropped.
1.6	The QRS does not introduce new attributions.	🟢	No attributions of any kind are present.

2. Focus, Tone & Audience

#	Description	Result	Comments
2.1	The QRS follows the tone of the ER, which is determined by the ER’s own language, phrasing, and framing.	🟢	Neutral, measured register matching the ER; British spellings (“Standardised”, “Haemoglobin”, “favourable”) carried through consistently.
2.2	The tone of the QRS is simultaneously expert, accessible, objective, and data-driven, but also empowering and encouraging	🟢	Quantified targets and thresholds throughout; at-a-glance closes on “Inexpensive, and directly measurable”.
2.3	The QRS reads as a trusted, knowledgeable guide rather than a prescriptive doctor	🟢	Content is stated as findings and ranges, not as orders.
2.4	The QRS avoids language that implies medical or clinical advice	🟢	No “should”, “must”, or prescriptive verbs in the QRS’s own voice; the template disclaimer is unchanged.
2.5	The QRS “presents information” instead of “providing guidance”, “recommending”, or “advising”	🟢	Cadence and protocol cells describe what trials and the ER state, not what to do.
2.6	The QRS never addresses “the reader” directly — it presents evidence, not guidance	🟢	No second-person pronoun occurs anywhere in the file.
2.7	The QRS is written in plain language, avoiding unnecessary medical jargon	🟢	Terms are spelled out where practical (“High-sensitivity C-reactive protein”, “non-heme iron”); remaining short forms (INR, eGFR, ARBs, NSAIDs) are standard reference-sheet notation for the stated audience.
2.8	Information is presented in a concise and very compact manner	🟢	All list items are single clauses; no ER explanatory prose survives.
2.9	It DOES NOT address the reader directly	🟢	Confirmed by full-text scan; no direct address.
2.10	The target audience is health- and longevity-oriented adults who are risk-aware, proactive, and actively seeking to optimize health or apply the intervention under review.	🟢	Functional-range targets (LDL 70–100 mg/dL, hs-CRP below 1.0 mg/L, ferritin 50–150 ng/mL) are pitched at self-monitoring users.
2.11	The target audience is willing to employ lifestyle and behavioral changes as well as follow protocols that may be inconvenient, costly, or require effort.	🟢	Split dosing, two-hourly mineral separation implied by the iron interaction, and an 11-marker panel assume a willing, effortful user.
2.12	The document is NOT written for the general population, who are unwilling to employ lifestyle and behavioral changes or follow protocols that may be inconvenient, costly, or require effort.	🟢	No general-population simplification; functional ranges are tighter than conventional lab cut-offs.
2.13	Framing, takeaways, and risk/benefit weighting throughout the document reflect this audience, including where an intervention’s signal for the average person differs from its signal for this audience.	🟢	At-a-glance condenses the ER’s “for someone who already tracks their own markers” framing into “Inexpensive, and directly measurable”.
2.14	The document’s own voice frames usage in longevity terms, not “anti-aging” (e.g., “anti-aging clinics”, “anti-aging community”, “anti-aging medicine”). Proper names that contain “anti-aging” (e.g., “American Academy of Anti-Aging Medicine”) are quoted verbatim.	🟢	“anti-aging” does not occur; the title uses “Health & Longevity”.
2.15	The document’s own voice uses formal clinical and scientific terminology, not colloquial or consumer-grade language (e.g., “oral medication” not “pill(s)”; “injection” not “shot”; “adverse event” not “bad reaction”). Direct quotes from sources are exempt.	🟢	Clinical register throughout (“Gastrointestinal intolerance”, “additive anticoagulant effect”); the plainer “stomach complaints” occurs only in At-A-Glance, where item 7.4 requires plain-language terms.

3. Template Integrity

#	Description	Result	Comments
3.1	The following labels and headings on the QRS are fixed and not modified: Card and section headings: “Protocol”, “Time to effect”, “Benefits”, “Risk & Side Effects”, “Monitoring”, “Qualitative Assessment”; Gate headings: “Contraindications”, “Key Interactions”; Tier labels: “High”, “Medium”, “Low”, “Speculative”; Table column headers in Monitoring: “Marker”, “Target”, “Why”	🟢	All headings, gate heads, tier labels and column headers match the template byte-for-byte.
3.2	All “…” from the [qrs_template] are present in the the QRS.	🟢	All 34 template variables present; the repeatable marker_#* and qualitative_item# rows are instantiated as marker_1–11 and qualitative_item_1–5.
3.3	Spans that are not addressed in a checklist item are left unchanged	🟢	Diff against the template shows the head, CSS block and the website="evidence_review", website="audit", website="full_review" spans unmodified.

4. Formatting

#	Description	Result	Comments
4.1	When the source ER section is empty, the QRS uses the ER’s own empty-state phrasing verbatim. Typical phrasings are “None documented in human trials to date” and “Not formally studied”	N/A	No source ER section is empty; the ER’s High-benefit tier carries explanatory prose rather than an empty-state phrase, and is handled under item 12.5.
4.2	Where the ER presents a bulleted item as “Label: content”, the QRS uses the ER’s bold label verbatim as the cell or row label.	🟢	Protocol cells reuse the ER bold labels “Standard extract dose”, “Anthocyanin target”, “Single versus split dosing” verbatim (ER lines 372, 374, 388).
4.3	Labels are not paraphrased, abbreviated, or invented.	🟢	Monitoring row labels match the ER biomarker table; time-to-effect labels are taken from the ER’s own wording in line 435, which supplies no bold labels of its own.
4.4	The QRS DOES NOT use emoji indicators (no 🟩, 🟥, 🟨, etc.). Color and emphasis are conveyed through CSS and bold labels.	🟢	No emoji characters in the file; the ER’s ⚠️ Conflicted markers were correctly dropped.
4.5	The QRS is designed to render on one A4 page. Any section that has more content in the ER than fits the per-section budget is condensed by the LLM, not extended onto a second page.	🟢	Single .sheet container with the template’s print rules intact; every section is condensed to headings-only phrasing, and the ER’s Context/Notes column was dropped entirely from the monitoring table.

---

5. Metadata

#	Description	Result	Comments
5.1	The metadata is placed inside a single HTML comment that is the first element after “<!doctype html>” and before any other comment, head, or body content.	🟢	Lines 2–14, immediately after <!doctype html> on line 1.
5.2	Inside that HTML comment the YAML block is delimited by a line “—” opening and a line “—” closing. Text before the opening “—” is permitted but is not parsed as YAML.	🟢	Opening --- at line 3, closing --- at line 13.
5.3	The metadata is not visible in any rendered view of the QRS and is not surfaced by any other element on the sheet.	🟢	Enclosed in an HTML comment; no metadata value is repeated in the body.
5.4	All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting.	🟢	Only duration: "00:03" is quoted, and it contains a colon.
5.5	The filename of the source ER is stated as “er_filename: [er_filename]”	🟢	Line 4: er_filename: black_chokeberry_2026-0825-0404_Opus_ER.md.
5.6	Version of the QRS.md file used to create the document is stated as “qrs_prompt_version: [Version of QRS.md]”	🟢	Line 5: qrs_prompt_version: 26.7.02, matching QRS.md.
5.7	Creation date and time of the document is stated as “qrs_creation_date: [YYYY-MMDD-HHMM]” (e.g., 2026-0501-1430)	🟢	Line 6: qrs_creation_date: 2026-0817-0613.
5.8	The nickname of the AI used to create the document is stated as “qrs_creator_ai_nickname: [qrs_creator_ai_nickname]”	🟢	Line 7: qrs_creator_ai_nickname: Opus.
5.9	The nickname of the AI is just a single word model name without version, etc. (e.g., Opus, Sonnet, Grok, Gemini, ChatGPT)	🟢	“Opus” — single word, no version.
5.10	The full name of the AI used to create the document is stated as “qrs_creator_ai_fullname: [qrs_creator_ai_fullname]”	🟢	Line 8: qrs_creator_ai_fullname: Opus 5.
5.11	The full name of the AI consists of the [qrs_creator_ai_nickname] and the model version number and no additional qualifier (e.g., Opus 4.6, Sonnet 3.2, Grok 4.5, Gemini 3.1, ChatGPT 5.4)	🟢	“Opus 5” — nickname plus version, no qualifier.
5.12	The filename of the document is stated as “qrs_filename: [filename of this document]”	🟢	Line 9 matches the file’s own name on disk.
5.13	All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting.	🟢	Re-verified across all nine keys; no stray whitespace or unnecessary quoting.

6. Page Title & Header

#	Description	Result	Comments
6.1	[page_title] is set to the [canonical_topic] of the ER frontmatter followed by “ - Quick Reference Sheet” (e.g., “Intervention - Quick Reference Sheet”). The [canonical_topic] is HTML-entity-encoded as needed (e.g., & for &)	🟢	Line 22: “Black Chokeberry for Health & Longevity - Quick Reference Sheet”.
6.2	[header_topic] is set to the [canonical_topic] of the ER frontmatter, with HTML entities encoded as needed (e.g., & for &)	🟢	Line 417: “Black Chokeberry for Health & Longevity”.
6.3	[header_subline_date] is set to [qrs_creation_date reformatted as MM/DD/YYYY]	🟢	Line 421: 08/17/2026, matching qrs_creation_date 2026-0817.
6.4	[header_subline_model] is set to [qrs_creator_ai_fullname]	🟢	Line 425: “Opus 5”.
6.5	No additional header content appears: no badge, version stamp, AKA / alternate names line, source-AI attribution, audit date, or QRS variant marker.	🟢	Header block is identical to the template apart from the two substituted variables.

7. At-A-Glance Section

#	Description	Result	Comments
7.1	[at_a_glance] is dense, execution-oriented summary of the ER Conclusion section	🟢	Compresses all three Conclusion paragraphs (ER lines 511–515) into pigment density, the two consistent effects, evidence quality, practical costs, and cost/measurability.
7.2	[at_a_glance] is no longer than 60 words	🟢	59 words.
7.3	Every fact in [at_a_glance] is supported by a distinct passage in the ER.	🟢	Each clause maps to a distinct Conclusion sentence: line 511 (pigment load, vessels, enzymes), 513 (thin, inconsistent, industry-funded), 515 (stomach complaints, iron, blood thinning, inexpensive, measurable).
7.4	It DOES NOT use acronyms or technical classifications that require specialist knowledge, uses plain-language terms instead	🟢	No acronyms; “plant-pigment loads”, “the body’s own antioxidant enzymes”, “stomach complaints”, “blocked iron uptake”, “mild blood thinning” are all lay phrasings.
7.5	It DOES NOT cite specific trials (names, years, sample sizes, p-values)	🟢	No trial, author, year or sample size appears.
7.6	It DOES NOT cite effect sizes, relative risks, or statistical results	🟢	No numeric effect estimates.

8. Contraindications

#	Description	Result	Comments
8.1	The section is derived from the ER Key Interactions & Contraindications section	🟢	All seven items trace to the ER “Populations who should avoid Black Chokeberry” list, ER lines 342–348.
8.2	[stop_items] represent the Contraindications from the ER	🟢	7 ER avoid-populations, 7 QRS items — complete one-to-one mapping.
8.3	Individual [stop_items] are formatted as <li></li>	🟢	Seven <li> elements inside the stop_items span (lines 569–579).
8.4	Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact.	🟢	Trailing rationale stripped throughout, e.g. ER “where oxalate and mineral handling are impaired” and “for whom no dosing or safety data … exist” are absent.
8.5	Parenthetical qualifiers from the ER bullet — time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely).	🟢	Retains INR above 3.0, the 14-day window, ferritin below 30 ng/mL, oxalate above 40 mg/day, “moderate-to-severe”, and eGFR below 30 mL/min/1.73 m².
8.6	When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol.	N/A	The ER uses no ranking notation in its contraindication bullets.
8.7	The section is left empty ONLY IF the ER’s Key Interactions & Contraindications section identifies no population, condition, or scenario for which the intervention should be avoided, deferred, or used only under specialist supervision.	🟢	The ER names seven such populations and the section is correspondingly populated.
8.8	If the section is left empty, an HTML comment inside the [stop_items] span records the ER basis for the absence, naming or quoting the ER text relied on. E.g.	N/A	The section is not empty.

9. Key Interactions

#	Description	Result	Comments
9.1	The section is derived from the ER Key Interactions & Contraindications section	🟢	All twelve items trace to ER lines 316–338.
9.2	[caution_items] represent the Key Interactions from the ER, excluding any that are already listed as Contraindications	🟢	12 ER interaction bullets, 12 QRS items; no avoid-population is duplicated here.
9.3	Individual [caution_items] are formatted as <li></li>	🟢	Twelve <li> elements inside the caution_items span (lines 587–607).
9.4	Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact.	🟢	Every ER rationale clause (“additive, … may raise bleeding risk”, “Weekly INR checks …”, “multivitamins at a different meal avoid this”) is stripped; the ER’s “Other interventions —” prefix is removed from the chemotherapy item.
9.5	Parenthetical qualifiers from the ER bullet — example drug lists, time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely).	🟢	All named example drugs are carried through for every class; only the ER’s inline definitions (“angiotensin receptor blockers, which relax vessels”, “non-steroidal anti-inflammatory drugs, everyday painkillers”) are trimmed.
9.6	When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol.	N/A	The ER uses no ranking notation in its interaction bullets.
9.7	The section is left empty ONLY IF the ER’s Key Interactions & Contraindications section identifies no interaction, additive effect, or exposure that changes how the intervention is used.	🟢	The ER names twelve interactions and the section is correspondingly populated.
9.8	If the section is left empty, an HTML comment inside the [caution_items] span records the ER basis for the absence, naming or quoting the ER text relied on. E.g.	N/A	The section is not empty.

10. Protocol

#	Description	Result	Comments
10.1	The section is derived from the ER Protocol section	🟢	All three cells map to ER Therapeutic Protocol bullets at lines 372, 374, 384 and 388.
10.2	The three sets of [action] items cover the three most important actionable implementation aspects from the ER Protocol section	🟢	Dose, anthocyanin threshold, and dose splitting/timing are the three executable levers; the ER’s competing-approach, half-life and modifier bullets are descriptive rather than actionable.
10.3	If less that three distinct actionable implementation aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing.	N/A	The ER supplies more than three actionable aspects; all three sets are used.
10.4	All used [action_#label], [action#value], [action#_sub] items are filled with meaningful content derived from the ER Protocol section.	🟢	All nine cells carry ER-derived content; no placeholder text remains.

11. Time to Effect

#	Description	Result	Comments
11.1	The three sets of [time] items cover the three most important time-to-effect aspects from the ER	🟢	Vascular (2 hours), lipid/inflammatory/enzyme (4–12 weeks) and cognitive (1 week) are the only three the ER states, at line 435.
11.2	The sets are picked and ordered by the magnitude of the related benefit	🟢	Vascular and lipid/inflammation/enzyme endpoints are Medium-tier benefits and lead; the Low-tier cognitive endpoint comes last.
11.3	If less that three distinct time-to-effect aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing.	N/A	The ER supplies exactly three aspects; all three sets are used.
11.4	All used [time_#label], [time#value], [time#_sub] items are filled with meaningful content derived from the ER.	🟢	All nine cells populated from ER line 435.
11.5	If the ER does not provide any information on time to effect, the section is removed completely from the Protocol Panel	N/A	The ER provides time-to-effect information, so the section is retained.

12. Benefits

#	Description	Result	Comments
12.1	The section is derived from the ER Expected Benefits section	🟢	Every listed benefit corresponds to an ER Expected Benefits heading (ER lines 152–220).
12.2	Key variables are [benefits_high], [benefits_medium], [benefits_low], [benefits_speculative]	🟢	All four spans present at lines 537, 540, 547, 554.
12.3	Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact.	🟢	Each tier is a semicolon-separated list of the ER’s benefit headings only; no magnitude paragraphs survive.
12.4	Parenthetical content — including effect sizes, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved.	🟢	No parentheses appear in any benefit item; the ER’s “⚠️ Conflicted” markers are removed.
12.5	If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing.	🟢	benefits_high carries style="display: none" with an HTML comment citing the ER’s “No claimed benefit reaches this evidence level” (lines 537–539).

13. Risks

#	Description	Result	Comments
13.1	The section is derived from the ER Potential Risks & Side Effects section	🟢	All ten risk items correspond to ER risk headings (ER lines 244–298).
13.2	Key variables are [risks_high], [risks_medium], [risks_low], [risks_speculative]	🟢	All four spans present at lines 619, 622, 628, 634.
13.3	Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact.	🟢	Each tier lists the ER headings only; no magnitude or mechanism text carried over.
13.4	Parenthetical content — including frequencies, severity grades, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved.	🟢	No parentheses in any risk item; the “roughly half of juice users” frequency is absent as required.
13.5	If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing.	N/A	All four ER risk tiers contain items, so no span needed hiding.

14. Monitoring

#	Description	Result	Comments
14.1	The section is derived from the ER Monitoring section	🟢	Marker, target and rationale text match the ER Monitoring Protocol & Defining Success table (ER lines 467–479).
14.2	All measurable/quantifiable biomarkers from the Monitoring section are listed	🟢	All 11 ER biomarker rows are present, in ER order, with targets reproduced exactly.
14.3	[monitoring_cadence] is populated with the monitoring cadence/frequency derived from the ER Monitoring section. It is not left with placeholder text or empty.	🟢	Lines 802–807 reproduce the ER cadence paragraph (line 465) plus the INR schedule from the ER’s INR row (line 478).

15. Qualitative Assessment

#	Description	Result	Comments
15.1	The section is derived from the ER Monitoring section	🟢	All five items come from the ER’s “Qualitative markers worth tracking alongside the labs” list (ER lines 483–487).
15.2	All subjective/qualitative biomarkers from the Monitoring section are listed	🟢	5 ER qualitative markers, 5 QRS items — gastrointestinal comfort, energy/exercise tolerance, bruising/bleeding, dizziness on standing, mental sharpness.

Issues 17/08/2026 06:19

Pass rate 100.00%. No issues found.